Alnylam Pharmaceuticals Inc (ALNY) — Upcoming Catalysts

FDA PDUFA dates, advisory-committee meetings, and Phase 2/3 readout windows for Alnylam Pharmaceuticals Inc, built from public data lanes (ClinicalTrials.gov and official sources). Each row links to its source.

For informational purposes only — not investment advice. Track ALNY live on Mooboard →

Later12

  • Apr 27, 2027
    Alnylam Pharmaceuticals Inc(ALNY)Phase 2/3 readout
    ALN-2232 · Phase 1 / Phase 2 · Obesity
    NCT07463846: A Study to Evaluate ALN-2232 in Participants With Obesity. Primary completion 2027-04-27 (estimated); status RECRUITING.
    ClinicalTrials.gov ↗
  • May 28, 2027
    Alnylam Pharmaceuticals Inc(ALNY)Phase 2/3 readout
    ALN-4324 · Phase 2 · Type 2 Diabetes Mellitus (T2DM)
    NCT07465224: A Study to Evaluate ALN-4324 on Insulin Sensitivity in Adults With Type 2 Diabetes Mellitus. Primary completion 2027-05-28 (estimated); status RECRUITING.
    ClinicalTrials.gov ↗
  • Jun 30, 2027
    Alnylam Pharmaceuticals Inc(ALNY)Phase 2/3 readout
    ALN-6400 · Phase 2 · Von Willebrand Disease (VWD); Heavy Menstrual Bleeding (HMB)
    NCT07575308: HMBeacon: A Phase 2 Study to Evaluate ALN-6400 in Adult and Adolescent Female Patients With VWD and HMB. Primary completion 2027-06-30 (estimated); status NOT_YET_RECRUITING.
    ClinicalTrials.gov ↗
  • Aug 9, 2027
    Alnylam Pharmaceuticals Inc(ALNY)Phase 2/3 readout
    Placebo · Phase 2 · Cerebral Amyloid Angiopathy
    NCT06393712: A Phase 2 Trial of ALN-APP in Patients With Cerebral Amyloid Angiopathy. Primary completion 2027-08-09 (estimated); status RECRUITING.
    ClinicalTrials.gov ↗
  • Aug 31, 2027
    Alnylam Pharmaceuticals Inc(ALNY)Phase 2/3 readout
    ALN-4324 · Phase 1 / Phase 2 · Obese or Overweight Healthy Volunteers; Type 2 Diabetes Mellitus (T2DM)
    NCT06845202: A Study to Evaluate ALN-4324 in Overweight to Obese Healthy Volunteers and in Overweight to Obese Patients With T2DM. Primary completion 2027-08-31 (estimated); status ACTIVE_NOT_RECRUITING.
    ClinicalTrials.gov ↗
  • Dec 27, 2027
    Alnylam Pharmaceuticals Inc(ALNY)Phase 2/3 readout
    Nucresiran · Phase 3 · Hereditary Transthyretin-Mediated Amyloidosis With Polyneuropathy; hATTR-PN
    NCT07223203: TRITON-PN: A Study to Evaluate the Efficacy and Safety of Nucresiran in Patients With Hereditary Transthyretin Amyloidosis With Polyneuropathy. Primary completion 2027-12-27 (estimated); status RECRUITING.
    ClinicalTrials.gov ↗
  • Jan 5, 2028
    Alnylam Pharmaceuticals Inc(ALNY)Phase 2/3 readout
    ALN-6400 · Phase 1 / Phase 2 · Hereditary Hemorrhagic Telangiectasia
    NCT06659640: A Study to Evaluate ALN-6400 in Healthy Volunteers and Patients With Hereditary Hemorrhagic Telangiectasia (HHT). Primary completion 2028-01-05 (estimated); status ACTIVE_NOT_RECRUITING.
    ClinicalTrials.gov ↗
  • Mar 31, 2028
    Alnylam Pharmaceuticals Inc(ALNY)Phase 2/3 readout
    Vutrisiran · Phase 3 · Transthyretin Amyloidosis (ATTR) With Cardiomyopathy
    NCT06679946: A Study to Evaluate Vutrisiran in Patients With Transthyretin Amyloidosis With Cardiomyopathy. Primary completion 2028-03-31 (estimated); status ENROLLING_BY_INVITATION.
    ClinicalTrials.gov ↗
  • Apr 1, 2028
    Alnylam Pharmaceuticals Inc(ALNY)Phase 2/3 readout
    ALN-AGT01 RVR · Phase 2 · Hypertension
    NCT07553442: A Study to Evaluate ALN-AGT01 RVR in Adult Patients With Mild to Moderate Hypertension Pretreated With Zilebesiran. Primary completion 2028-04-01 (estimated); status RECRUITING.
    ClinicalTrials.gov ↗
  • May 18, 2030
    Alnylam Pharmaceuticals Inc(ALNY)Phase 2/3 readout
    Mivelsiran · Phase 2 · Down Syndrome-Associated Alzheimer's Disease (DS-AD)
    NCT07636811: A Study to Evaluate Mivelsiran in Adult Participants With Early-Stage Down Syndrome-Associated Alzheimer's Disease (DS-AD). Primary completion 2030-05-18 (estimated); status NOT_YET_RECRUITING.
    ClinicalTrials.gov ↗
  • May 28, 2030
    Alnylam Pharmaceuticals Inc(ALNY)Phase 2/3 readout
    Nucresiran · Phase 3 · Transthyretin Amyloidosis With Cardiomyopathy
    NCT07052903: TRITON-CM: A Study to Evaluate Nucresiran in Patients With Transthyretin Amyloidosis With Cardiomyopathy. Primary completion 2030-05-28 (estimated); status RECRUITING.
    ClinicalTrials.gov ↗
  • Sep 30, 2030
    Alnylam Pharmaceuticals Inc(ALNY)Phase 2/3 readout
    Zilebesiran · Phase 3 · High Risk Cardiovascular Disease; Hypertension
    NCT07181109: Zilebesiran in Patients With Hypertension Not Adequately Controlled and With Either Established Cardiovascular Disease or High Risk for Cardiovascular Disease. Primary completion 2030-09-30 (estimated); status RECRUITING.
    ClinicalTrials.gov ↗

How Alnylam Pharmaceuticals Inc has moved — past-year price reactions

How binary is ALNY? Its typical daily move, how often it swings ±10%, and its biggest single-day moves over the last year — useful context for sizing around a catalyst.

1.4%
typical day (1Y)
1
±10% days
45.5%
annualized vol
250
trading days
Largest single-day moves
  • -28.3%2026-07-30no matched headline
  • +7.2%2026-08-03no matched headline
  • -6.9%2026-01-12no matched headline
  • +6.7%2026-03-25no matched headline
  • -6.7%2025-10-30no matched headline
  • -6.1%2025-12-08no matched headline

Real daily price moves over the past year — not every move is a catalyst, and headlines (where shown) are a possible same-day driver, not confirmed causation.

Alnylam Pharmaceuticals Inc — active clinical pipeline

Alnylam Pharmaceuticals Inc's registered Phase 1–3 programs by asset and indication, derived from ClinicalTrials.gov.

15 assets18 programsPh1 7Ph2 7Ph3 4
AreasOncologyMetabolicNeuroscienceCardiovascularRare / GeneticOther
NucresiranRare / Genetic
Phase 3
Hereditary Transthyretin-Mediated Amyloidosis With PolyneuropathyTransthyretin Amyloidosis With Cardiomyopathy
VutrisiranRare / Genetic · Transthyretin mRNA
Phase 3
Transthyretin Amyloidosis (ATTR) With Cardiomyopathy (2)
ZilebesiranCardiovascular
Phase 3
High Risk Cardiovascular Disease
ALN-6400Rare / Genetic
Phase 2
Hereditary Hemorrhagic TelangiectasiaVon Willebrand Disease (VWD)
ALN-APPRare / Genetic
Phase 1
Early-Onset Alzheimer Disease
Phase 2
Cerebral Amyloid Angiopathy
ALN-2232Metabolic
Phase 2
Obesity
ALN-4324Metabolic
Phase 2
Type 2 Diabetes Mellitus (T2DM) (2)
ALN-AGT01 RVRCardiovascular
Phase 2
Hypertension
MivelsiranNeuroscience
Phase 2
Down Syndrome-Associated Alzheimer's Disease (DS-AD)
ALN-4285Other
Phase 1
Healthy volunteers
ALN-4915Other
Phase 1
Healthy volunteers
ALN-5288Neuroscience
Phase 1
Alzheimer's Disease
ALN-6222Metabolic
Phase 1
Obesity
ALN-BCATOncology
Phase 1
Advanced Hepatocellular Carcinoma
ALN-HTT02Neuroscience
Phase 1
Huntington's Disease

Active registered Phase 1–3 trials from ClinicalTrials.gov — not the company's official IR pipeline (no preclinical or undisclosed assets). Grouped by trial intervention name; therapeutic area is auto-categorized. Each indication links to its trial. Molecular targets sourced from ChEMBL (EMBL-EBI).

See the full biopharma catalyst calendar across all covered companies.